Global Beta-lactam and Beta-lactamase Inhibitors Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Beta-lactam and Beta-lactamase Inhibitors Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Beta-lactam antibiotics are a class of antibiotics consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures. This includes penicillin derivatives, cephalosporins, monobactams, and carbapenems. Beta-lactamase inhibitors are a class of medicine that block the activity of beta-lactamase enzymes (also called beta-lactamases), preventing the degradation of beta-lactam antibiotics.

Market Overview:

The latest research study on the global Beta-lactam and Beta-lactamase Inhibitors market finds that the global Beta-lactam and Beta-lactamase Inhibitors market reached a value of USD 17249.4 million in 2022. It’s expected that the market will achieve USD 1019.78 million by 2028, exhibiting a CAGR of -37.59% during the forecast period.

Pharmaceutical consumption in low- and middle-income countries continue to increase

In general, global antibiotic use continues to grow steadily, mainly driven by increased use in low- and middle-income countries. Driven by increased use in countries such as South Africa and India, where antibiotics are ubiquitous over the counter in various pharmacies, as well as in some impoverished areas. Due to many reasons such as sanitation facilities and standard systems in low- and middle-income countries and people's hygiene attitudes, people may be more likely to be infected with bacteria. With the rising income level and consumption level of people in low- and middle-income countries, the purchase of various antibiotics will increase, thereby increasing the demand for Beta-lactam antibiotics. The continuous increase in pharmaceutical consumption in low- and middle-income countries will be one of the important reasons for the development of the industry.

Resistance to antibiotics

Beta-lactam antibiotics are very common antibiotics used to treat various bacterial infections. Currently, these drugs are readily available over-the-counter (OTC) and available without a prescription in most countries, leading to overuse or abuse. The overuse or misuse of Beta-lactam antibiotics has led to tolerance problems. Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to drugs, making infections more difficult to treat and the risk of disease transmission, serious illness, and death increase. Infections become increasingly difficult or impossible to treat due to drug resistance, as antibiotics and other antimicrobial drugs become ineffective. The economic costs of antimicrobial resistance are substantial. In addition to death and disability, prolonged illness can lead to prolonged hospital stays, the need for more expensive medications, and a heavy financial burden for those affected. Beta-lactam antibiotics are being used more cautiously due to antibiotic resistance. Relevant research institutions have called for reducing the use of antibiotics and strengthening diagnosis and antibiotic stewardship. Therefore, the market demand for Beta-lactam antibiotics may decrease. In general, drug resistance is one of the important issues facing the development of the industry.

Development of combined formulations

After the pathogenic bacteria are in contact with a certain antibacterial drug many times, the sensitivity of the pathogenic bacteria to the drug decreases or even disappears, resulting in a decrease in the efficacy of the drug against the pathogenic bacteria or even ineffectiveness. -Lactam antibiotics are the most commonly used antibiotics in clinical practice. However, due to its long-term clinical application, most bacteria have been resistant to it. The main mechanism of bacterial resistance to -lactam antibiotics is the inactivation of the -lactam ring of the -lactamase hydrolyzate. -lactamase inhibitors can inhibit most -lactamases and restore the antibacterial activity of -lactam antibiotics. Therefore, the status of -lactam antibiotics combined with -lactamase inhibitor mixtures in clinical anti-infection has been continuously improved, and it has become an important choice for the clinical treatment of multi-drug resistant bacterial infections. The development of combined formulations is one of the important opportunities for the development of the industry.

Region Overview:

In 2021, the share of the Beta-lactam and Beta-lactamase Inhibitors market in China stood at 44.85%.

Company Overview:

Pfizer
Pfizer is an American multinational pharmaceutical and biotechnology company. The company mainly focuses on rare diseases, internal medicine, inflammation and immunology, vaccines, oncology, anti-infective drugs, and other fields.

Novartis AG

Novartis AG is a multinational pharmaceutical and biotechnology company headquartered in Basel, Switzerland. Its core businesses are in a variety of patent medicines, consumer healthcare, generic medicines, eye care, and animal health. Novartis AG uses innovative science and technology to solve some of society's most challenging healthcare problems.

GlaxoSmithKline

GlaxoSmithKline is a pharmaceutical, biological, and healthcare company. GlaxoSmithKline is an R&D-based company covering the anti-infective, central nervous system, respiratory, gastroenterology/metabolism, oncology, and vaccine fields. Its business scope also includes leading oral health care, nutritional beverages, and some over-the-counter drug businesses.

Pfizer is one of the major players operating in the Beta-lactam and Beta-lactamase Inhibitors market, holding a share of 4.15% in 2022.

Segmentation Overview:

Penicillin
Penicillin refers to a class of antibiotics containing penicillane in the molecule, which can destroy the cell wall of bacteria and play a bactericidal effect during the reproductive period of bacterial cells.
Cephalosporin
Cephalosporins are beta-lactam antimicrobials used to manage a wide range of infections from gram-positive and gram-negative bacteria.
Carbapenem
Carbapenems exhibit unique pharmacological properties and are typically used to treat complicated bacterial infections.
Monobactam
Monobactams are monocyclic and bacterially-produced -lactam antibiotics.
Combination
This type refers to a combination of Beta-lactamase Inhibitors and Beta-lactam antibiotics.

By type,Cephalosporin segment accounted for the largest share of market in 2021.

Application Overview:

Urinary Tract Infection (excluding CUTI)
Divided according to the treatment of different diseases. A urinary tract infection (UTI) is an infection of any part of the urinary system. The urinary system includes the kidneys, ureters, bladder, and urethra.
Respiratory Infection
Respiratory Infection is an infection of parts of the body that involve breathing, such as the sinuses, throat, airways, or lungs.
Skin Infection
Skin Infection is when bacteria (bacteria, viruses, or fungi) infect people's skin and sometimes the deep tissue beneath the skin.
Complicated Urinary Tract Infection (CUTI)
Complicated Urinary Tract Infection (CUTI) is a urinary tract infection that occurs in patients with structural or functional abnormalities of the urogenital tract.
Complicated Intra-Abdominal Infections (CIAI)
Complicated Intra-Abdominal Infections (CIAI) are usually defined as abscess formation or peritonitis.
Nosocomial Pneumonia
Nosocomial Pneumonia is a lower respiratory tract infection with no incubation period on admission and clinical symptoms after 2 days or more of hospitalization.
Blood Stream Infection
Bloodstream infection (BSI) is an infectious disease defined as the presence of live bacterial or fungal microorganisms in the bloodstream that causes or has caused an inflammatory response characterized by clinical, and laboratory changes.

The market's largest segment by application is the segment Respiratory Infection, with a market share of 25.75% in 2021.

Key Companies in the global Beta-lactam and Beta-lactamase Inhibitors market covered in Chapter 3:

Teva Pharmaceutical Industries Ltd.
Eddingpharm
Pfizer Inc.
Shionogi and Co., Ltd.
Novartis International AG
Merck & Co. lnc.
GlaxoSmithKline
Roche Holding AG
AbbVie
Viatris

In Chapter 4 and Chapter 14.2, on the basis of types, the Beta-lactam and Beta-lactamase Inhibitors market from 2018 to 2029 is primarily split into:

Penicillin
Cephalosporin
Carbapenem
Monobactam
Combination
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Beta-lactam and Beta-lactamase Inhibitors market from 2018 to 2029 covers:

Urinary Tract Infection (excluding CUTI)
Respiratory Infection
Skin Infection
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (ClAI)
Nosocomial Pneumonia
Blood Stream Infection
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)